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Summary: Fracture-related infection (FRI) is a major complication
in musculoskeletal trauma and one of the leading causes of
morbidity. Standardization of general treatment strategies for FRI
has been poor. One of the reasons is the heterogeneity in this patient
population, including various anatomical locations, multiple fracture
patterns, different degrees of soft-tissue injury, and different patient
conditions. This variability makes treatment complex and hard to
standardize. As these infections are biofilm-related, surgery remains
the cornerstone of treatment, and this entails multiple key aspects
(eg, fracture fixation, tissue sampling, debridement, and soft-tissue
management). Another important aspect, which is sometimes less
familiar to the orthopaedic trauma surgeon, is systemic antimicrobial
therapy. The aim of this article is to summarize the available
evidence and provide recommendations for systemic antimicrobial
therapy with respect to FRI, based on the most recent literature
combined with expert opinion.
Key Words: fracture-related infection, antibiotics, biofilm, suppres-
sive therapy, antimicrobial therapy, consensus, fracture, infection
Level of Evidence: Therapeutic Level V. See Instructions for
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INTRODUCTION
The aim of this article is to summarize the available
evidence and provide recommendations for systemic antimicro-
bial therapy with respect to fracture-related infection (FRI)
patients, based on the most recent literature combined with
expert opinion.1 For this purpose, organizations such as the AO
Foundation, the European Bone and Joint Infection Society (EB-
JIS), the Orthopaedic Trauma Association (OTA), and the PRO-
IMPLANT Foundation have collaborated in an FRI Consensus
group. Many of the recommendations provided in this review
are based on expert opinion because clinical data from controlled
trials are not available, and the likelihood that studies for ratio-
nalizing the management of FRI will be conducted remains low.
Pathophysiology
Biofilm development on the surface of implants is the
main hindrance of infection eradication. Bacteria growing in
biofilms are proven to be up to 1000 times more resistant to
antibiotics than in the planktonic state,2 and the antibiotic effect
decreases even more with increasing age of biofilms.3 In peri-
prosthetic joint infection (PJI), it was shown that failure rates of
antibiotic therapy significantly increase with implant retention if
symptoms have lasted for more than 4 weeks before treatment.4
In FRI, based on biofilm formation, different time-related
classifications have been proposed (such as early, delayed, and
late-onset infections vs. acute and chronic infections), but strong
evidence to support one classification over another is lacking.3
Surgical Treatment Concepts
There are no randomized controlled trials on surgical
treatment strategies and duration of systemic antimicrobial therapy
in FRI. Prompt debridement should always be performed to
reduce the bacterial load (bioburden) at the site of infection,
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thereby increasing the efficacy of antimicrobials and reducing the
risk of developing antimicrobial resistance. Debridement will also
reduce the local inflammatory response and risk of developing
chronic infection/osteomyelitis. The application of local antimi-
crobials can be an important adjunct in the treatment of FRI and
should be considered, especially in cases with a remaining bony
defect or “dead space.”5 Systemic antimicrobial therapy in FRI is
guided by 2 main surgical treatment concepts:
1. The first concept consists of Debridement, Antimicrobial
therapy, and Implant Retention (DAIR).
2. The second consists of debridement, implant removal—in
case the fracture has healed—or exchange (in 1 or multiple
stages), combined with antimicrobial therapy.
Based on these concepts, treatment duration and mode
of administration will be discussed below (Fig. 1).
Removal of the Implant in Case of Fracture
Consolidation
When FRI occurs after the fracture healed and
a debridement has been performed with complete removal
of the implant, the treatment duration can be extrapolated
from that for acute osteomyelitis. Four to 6 weeks of
intravenous (IV) antibiotics has been standard practice for
many years.6,7 The prolonged use of IV antibiotics was based
on recommendations by Waldvogel et al8 in 1970, with beta-
lactams being the main available class of antibiotics for IV
and oral routes. The key factor however is to achieve high
enough drug levels in blood and bone, rather than the route of
administration. Newer oral agents with better bioavailability
and acceptable bone penetration are now available. The OVI-
VA trial compared intravenous with oral antibiotics and
FIGURE 1. Duration of antimicrobial therapy according to treatment strategy.
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Flucloxacillin§ 2 g 6-hourly IV
and
Rifampicin† 300–450 mg 12-hourly PO
Followed by oral therapy (according to susceptibility pattern)
Rifampicin† 300–450 mg 12-hourly PO
and




Doxycycline/minocycline or 100 mg 12-hourly
Clindamycin or 600 mg 8-hourly
Fusidic acid 500 mg 8-hourly
Oxacillin/methicillin-resistant Vancomycin‡ or Loading dose: 25–30 mg/kg,
Maintenance dose: 15 mg/kg
12-hourly IV
Daptomycin or 8–10 mg/kg Once a day
Teicoplanin 12 mg/kg Once a day (with an extra loading
dose at 12 hours)
and
Rifampicin† 300–450 mg 12-hourly
Followed by oral therapy (according to susceptibility pattern)
Rifampicin† 300–450 mg 12-hourly PO
and




Doxycycline/minocycline or 100 mg 12-hourly
Clindamycin or 600 mg 8-hourly
Fusidic acid 500 mg 8-hourly
Rifampicin-resistant Intravenous treatment according to susceptibility, followed by oral suppression until there is sufficient bony healing, so
that the implant can be removed
Streptococcus spp.
Penicillin G§ or 5 million units 6-hourly IV
or or
4 million units 4-hourly
Ceftriaxone§ 2 g Once a day
Followed by oral therapy (according to susceptibility pattern)
Amoxicillin or 1 g 6- to 8-hourly PO




Penicillin-susceptible Ampicillin 2 g 6-hourly IV
and
Gentamicin¶ 3 mg/kg Once a day
Followed by oral therapy (according to susceptibility pattern)
Amoxicillin 1 g 6- to 8-hourly PO
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Penicillin-resistant Vancomycin‡ or Loading dose: 25–30 mg/kg;
Maintenance dose: 15 mg/kg
12-hourly IV
Daptomycin or 8–10 mg/kg Once a day
Teicoplanin 12 mg/kg Once a day (with an extra loading
dose at 12 hours)
Followed by oral therapy (according to susceptibility pattern)
Linezolid* (maximum treatment
duration of 4 weeks)








Followed by oral therapy (according to susceptibility pattern)
Ciprofloxacin║ or 750 mg 12-hourly PO




Piperacillin/tazobactam or 4.5 g 6- to 8-hourly IV
Meropenem or 2 g 8-hourly
Ceftazidime 2 g 8-hourly
and
Tobramycin (short course only
with careful monitoring) or
5 mg/kg Once a day
Gentamicin (short course only
with careful monitoring) or
5 mg/kg Once a day
Amikacin (short course only with
careful monitoring)
15 mg/kg Once a day
Followed by oral therapy (according to susceptibility pattern)
Ciprofloxacin║ or 750 mg 12-hourly PO





Intravenous treatment according to susceptibility, followed by oral suppression until there is sufficient bony healing, so






Penicillin G§ or 5 million units 6-hourly IV
Ceftriaxone 2 g Once a day
Followed by oral therapy (according to susceptibility pattern)
Amoxicillin or 1 g 6- to 8-hourly PO
Doxycycline 100 mg 12-hourly
(and rifampicin†#) 300–450 mg 12-hourly
Gram-negative (eg,
Bacteroides)
Ampicillin/sulbactam§** 3 g 8-hourly IV
Followed by oral therapy (according to susceptibility pattern)
Metronidazole or (400)-500 mg 8-hourly PO
Clindamycin or 600 mg 8-hourly
Amoxicillin 1 g 6- to 8-hourly
Candida spp.
Fluconazole-susceptible An echinocandin for up to 2 weeks
Followed by oral therapy
(according to susceptibility
pattern)
Fluconazole 400 mg Once a day
(continued on next page )
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demonstrated noninferiority of oral antibiotics.9,10 In this trial,
patients in the oral arm received up to 1 week of IV anti-
biotics. It is therefore recommended that patients only receive
empiric broad-spectrum IV antibiotics until culture and sen-
sitivity results are available, and then, if there are appropriate
bioavailable oral agents (Table 1), they can be switched to
oral antibiotics to complete a period of 6 weeks from implant
removal.7,9,10
Debridement, Antimicrobial therap, and
Implant Retention
No published data are available regarding the dura-
tion of antimicrobial treatment in FRI with a retained
implant. Treatment is likely to eradicate the infection only
if a biofilm-active antibiotic agent is used. Biofilm activity
has been clearly demonstrated only for rifampicin combi-
nations against staphylococci and fluoroquinolones against
Gram-negative bacteria.11–13 When biofilm-active therapy
is possible, a total treatment duration of 12 weeks is rec-
ommended, with an initial IV treatment until the patient
(eg, polytrauma or intensive care unit patient) and the soft
tissue are settled and full antibiotic susceptibility results of
the cultures are available.9 As previously mentioned, IV
treatment can be as short as 1 week or even less. When
no biofilm-active antibiotics can be given due to resistance,
patient intolerance, or potential drug interactions, infec-
tions are classified as “difficult-to-treat” and may not be
eradicated by antibiotics as long as the implants are
retained. In this situation, FRI can likely be suppressed
but not eradicated. Similarly, if the first debridement takes
place more than 4 weeks after the start of symptoms and the
implant cannot be removed/exchanged, antimicrobial ther-
apy may not achieve eradication of the established older
biofilms and again may be suppressive rather than eradica-
tive. If a suppressive approach is chosen, antimicrobials
should be continued until the fracture is consolidated to
the extent that the implant can be removed without com-
promising stability.14 One to 2 weeks of continuation after
removal is indicated. Importantly, an initially suppressive
approach will not be successful if fracture healing is esti-
mated to be very unlikely (eg, instability of the construct)
or if no signs of fracture healing can be found over the
course of suppressive treatment. There is a lack of pub-
lished data comparing different suppressive regimens in
FRI. As guidance, suppressive therapy needs to be tailored
to the susceptibility of the responsible pathogen(s), should
have low propensity to induce resistance, should be orally
available, and the dosage and antibiotic class should be
able to control the infection with minimal side effects
and toxicity.
Debridement with One- or Two-Stage Exchange of
the Implant
A 1- or 2-stage exchange is performed if patients
without bone union do not qualify for eradicative or
suppressive treatment with implant retention. A total duration







Fluconazole-resistant Discuss with infectious diseases/
microbiology
eg, voriconazole 200 mg 12-hourly PO






3 g 8-hourly IV
Followed by oral therapy
Rifampicin† 300–450 mg 12-hourly PO
and
Levofloxacin 500 mg 12-hourly
*Laboratory testing weekly: leukocytes, C-reactive protein, creatinine/eGFR, and liver enzymes (AST/SGOT and ALT/SGPT). Dose adjustment according to renal function and
body weight (,40 kg or .100 kg).
†Rifampicin is added to the IV treatment when wounds are dry and all drains are removed. It is administered only after the new fixation device is implanted. Rifampicin is not used
if the fixation device was removed; in patients older than 75 years, rifampicin is reduced to 2 · 300 mg. Caution for drug interactions.
‡Check vancomycin trough concentration (blood analysis before next dose) before the fourth dose; therapeutic range: 15–20 mg/mL.
§Penicillin allergy of NON-type 1 (eg, skin rash): cefazolin (3 · 2 g IV) or similar cephalosporin. In case of anaphylaxis (ie, type 1 allergy such as Quincke’s edema,
bronchospasm, and anaphylactic shock) or cephalosporin allergy: vancomycin (according to protocol) or daptomycin (1 · 8–10 mg/kg IV).
¶Add only, if gentamicin high-level (HL) is tested susceptible (consult your microbiology laboratory). In gentamicin HL-resistant E. faecalis: gentamicin is replaced by ceftriaxone
(1 · 2 g IV). Use gentamicin with caution because of risk of ototoxicity and nephrotoxicity. Monitor levels and keep predose level ,1 mg/L. For prolonged courses, perform baseline
audiometry.
║Start when wounds are dry and after reduction of the initial bacterial load (adequate debridement).
#For Gram-positive anaerobes, rifampicin combination should only be considered with Cutibacterium acnes.
**Ampicillin/sulbactam is equivalent to amoxicillin/clavulanic acid (3 · 2.2 g IV).
††If confirmatory signs for infection (eg, wound breakdown with a visible implant), antibiotic treatment should be chosen to cover the most likely pathogens, based on local
preferences.
PO, per oral.
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of 12 weeks of biofilm-active therapy is recommended in a 1-
stage exchange with intravenous treatment until full antibiotic
susceptibility results of the cultures are available.
A 2-stage exchange with an implant-free interval at the
site of infection can be required if no biofilm-active
antimicrobial is available, surgical factors are unfavorable
(eg, soft-tissue status), or suppressive therapy is not an
adequate option. This requires temporary stabilization of the
fracture, with the type of fixation being at the discretion of the
treating surgeon. During the implant-free interval, 6 weeks of
antibiotic treatment without biofilm activity is recommended,
starting with intravenous treatment until full antibiotic
susceptibility results of the cultures are available. After the
first 6 weeks of treatment, 2 different approaches exist with
no consensus and a lack of data on the optimal continuation
therapy. One approach consists of an immediate reimplanta-
tion followed by further 6 weeks of biofilm-active treatment.
The other allows a 2-week antibiotic-free interval before
reimplantation to see whether clinical signs of infection
reoccur and to enable regrowth of potential residual bacteria.
If no clinical signs of infection occur and tissue cultures from
reimplantation stay negative, the antibiotics that were re-
started after implantation can be stopped (Fig. 1).
It should be acknowledged that in cases of FRI, there is
often the presence of a fracture (ie, instability). A period of 6
weeks without fracture stability is not advisable. External
fixation could be used, although chances are higher of
developing an infection (ie, pin tracts) after a period of
long-term external fixation followed by internal fixation.
Therefore, in some cases, a two-stage exchange with a short
interval can be considered. Here, a period of 1–2 weeks of
temporary fracture fixation, again the type of fixation is at the
discretion of the treating surgeon, is advisable until culture
results are known and targeted systemic and local antibiotic
therapy can be started. The total treatment duration remains
12 weeks.
Cases of segmental bone resection without internal
fixation (eg, ring fixator) are an exception. Here, all dead and
infected bone should be removed, and the multidisciplinary
team needs to decide whether a long course of antibiotic
treatment is necessary. It may be sufficient to give 2 weeks of
antimicrobial therapy to eradicate the residual contamination
in the soft tissue.
The experts acknowledge that there are multiple
different treatment strategies available, with a lack of
evidence supporting one over the other (Fig. 1). In addition,
scientific data on duration of antimicrobial treatment in FRI
remain scarce. They suggest that every patient receives an
individualized treatment plan that is confirmed by the multi-
disciplinary team. Furthermore, future studies are warranted
to give better insights into the optimal treatment strategy.
Empirical Antibiotic Therapy
In case of suspected FRI, antibiotics should not be
started before the initial surgical debridement unless the
patient is septic according to the 2016 international definition
of sepsis.15 Multiple tissue samples for microbiology and
histopathology should be taken intraoperatively, using
separate sterile instruments for each sample at the start of
the debridement.16 If there are confirmatory signs of FRI
(eg, pus) or there is a high suspicion due to the presence of
suggestive signs,16,17 empiric intravenous antimicrobial ther-
apy should be started immediately after perioperative tissue
sampling. Empiric antimicrobial treatment should be contin-
ued until the microbiology results are available and then re-
assessed.17 The choice of empiric therapy depends on the
local epidemiology of antibiotic resistance rates, antibiotic
formularies, and risk factors of each individual patient (ie,
previous antibiotics, comorbidities, allergies, previous hospi-
talizations, previous debridements at the same site, and pre-
viously recovered pathogens). Initially, empiric therapy
should be broad-spectrum, including a lipopeptide or a glyco-
peptide and an agent covering Gram-negative bacilli; there-
after, it should be adapted according to culture results as soon
as possible.
All patients who are started on IV antibiotics should be
tested for baseline inflammatory markers, full blood count,
electrolytes, and liver and renal function tests and should be
monitored at least once weekly (depending on host status) in
the acute phase of their illness as common side effects of
high-dose IV antibiotics include bone marrow suppression,
hepatitis, and nephritis. The multidisciplinary team plays an
important role in assessing these side effects.
Targeted Antimicrobial Therapy
Treatment of Staphylococcus Species
Staphylococcus aureus
In methicillin-susceptible Staphylococcus aureus
(MSSA), IV flucloxacillin is the first choice initially. Garzoni
et al studied the interactions of continuous flucloxacillin and
oral rifampicin in 15 patients. The combination with rifampi-
cin increased flucloxacillin levels (by 44.5%); however, in
monotherapy, the plasma-free drug level of flucloxacillin also
exceeded the minimal inhibitory concentration (MIC) for S.
aureus by several fold.18 In other studies, a lowered serum
level of flucloxacillin was observed.19 The expert group rec-
ommends a dose of 2-g flucloxacillin every 6 hours. When S.
aureus is methicillin-resistant (MRSA), IV vancomycin is
recommended initially. Careful monitoring for nephrotoxicity
is essential, with therapeutic serum values between 15 and 20
mg/L. However, both glycopeptides (vancomycin and teico-
planin) and daptomycin demonstrate low cure rates when
given as monotherapy in experimental implant-associated
infection.20,21 In cases of vancomycin allergy, daptomycin
can be considered.
Coagulase-Negative Staphylococci
Coagulase-negative staphylococci such as Staphylococ-
cus epidermidis are treated like MRSA if they are methicillin-
resistant (MRSE). Methicillin susceptibility testing may be
difficult in some strains. Expression of resistance is affected
by test conditions and resistance is often heterogeneous, with
only a proportion of cells showing resistance. If mecA is
absent, strains can be treated as for MSSA.
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General Principles
For Staphylococcus species, the curative treatment of
choice with implants in situ is a combination of rifampicin
with a second active antibiotic after the initial IV period.
Rifampicin is a bactericidal agent active against growing
and nongrowing staphylococci in biofilms.22–25 However,
monotherapy with rifampicin leads to rapid emergence of
resistance.11 The risk of superinfection with (a) rifampicin-
resistant strain(s) increases when the bacterial load is high and
the wound is oozing or drains are present.26,27 The recom-
mended dose of oral rifampicin is 300–450 mg twice or 600–
900 mg once daily started after debridement and when the
wound has sealed.27 The expert group recommends liver
function tests at baseline and thereafter if there are clinical
concerns.28
Once the wound is stable, drains are out, and microbi-
ology results are available, it is recommended to switch to an
oral antibiotic in combination with rifampicin. The first
choice is a fluoroquinolone. Patients should be warned about
adverse effects including Achilles tendon tendinitis and
photosensitivity. Second-line antimicrobials combined with
rifampicin include sulfamethoxazole/trimethoprim in high
dose (960 mg, 8 hourly). Other second-line agents include
doxycycline or minocycline and fusidic acid. In some cases,
where there is resistance or intolerance to the other agents,
oral pristinamycin can be used.29,30 The dosages for the afore-
mentioned antimicrobials are summarized in Table 1.
Linezolid in monotherapy is an alternative agent. In
animal models, the success rate of monotherapy appears
inferior to a combination of rifampicin and linezolid. The
combination therapy results in 75%–95% clearance of plank-
tonic MRSA and a cure rate of 50%–60% with implants.31
Rifampicin however may reduce the levels of linezolid and
may lead to subinhibitory concentrations.32 Further studies
are needed regarding combination therapy with rifampicin
and linezolid. If this regimen is used, it is important to check
lactate and full blood counts weekly, as linezolid can cause
severe reversible pancytopenia, lactate acidosis, and irrevers-
ible neurotoxicity.33 It also interacts adversely with many
psychiatric drugs risking hypertensive crises and serotonin
syndrome (serotonin uptake inhibitors).
Monotherapy with fluoroquinolones is not recommended
for staphylococcal infections because of the rapid emergence of
resistance and high treatment failure rate.34,35 Moxifloxacin has
a lower MIC for staphylococci than levofloxacin and ciproflox-
acin. In addition, it has the advantage that no dose adjustment
is necessary in case of renal insufficiency.36 Studies have
shown that moxifloxacin has a lower risk of emergence of
antimicrobial resistance than other fluoroquinolones.35,37–39
In addition, studies on tuberculosis have shown a lowering
of moxifloxacin serum levels by 30% when used in combina-
tion with rifampicin.40 Wouthuyzen-Bakker et al39 observed
a success rate of 89% using a moxifloxacin/rifampicin combi-
nation in patients with early acute PJI caused by MSSA. More
studies are necessary before recommending moxifloxacin/
rifampicin as the preferred first-line per oral therapy.
The use of clindamycin in combination with rifampicin
as an oral alternative is controversial. Bernard et al showed
a dramatic reduction of clindamycin serum concentration
when used in combination with rifampicin. Rifampicin is
a potent cytochrome P450 inducer, while clindamycin is
metabolized through CYP3A4, a member of this cytochrome
P450 system and one of the main enzymes involved in the
metabolism of drugs. This interaction enhances the elimina-
tion of clindamycin in combination with rifampicin.41 How-
ever, since clindamycin can be given at a high dose (600–900
mg every 6–8 hours), therapy with this antibiotic may be
sufficient.42
Treatment of Streptococcus Species
The expert group recommendations for streptococcal
infections are based on the IDSA PJI guidelines.34 Beta-
lactam antibiotics are the agent of choice, although it is
known that antibiotics that target the cell wall may be inef-
fective once the initial phase has passed, due to the slower
growth rate of adherent bacteria, during which cell wall syn-
thesis is reduced.43 However, poor efficacy of these beta-
lactams has not been demonstrated in streptococcal implant-
associated infections.13,44–46 Intravenous beta-lactam therapy
should be given for up to a week followed by oral therapy
with amoxicillin (Table 1).
After prompt debridement, it is recommended (if there
is no history of penicillin allergy) to start with IV benzyl
penicillin 4 million units (2.4 g) every 4 hours (24 MU/day)
or 5 million units (3.0 g) every 6 hours (20 MU/day). When
the MIC value is ,0.1 mg/L, the dosage can be adjusted to
12–18 MU/day. If there is a history of nonimmediate, non-
severe penicillin allergy (eg, a delayed rash), an alternative is
ceftriaxone or cefotaxime (Table 1). In case of penicillin
allergy, trimethoprim/sulfamethoxazole, doxycycline, and
clindamycin are alternatives, depending on susceptibility
testing.
Despite good activity of rifampicin against planktonic
streptococci, it has been observed in clinical studies that it has
no activity on streptococcal biofilms.47,48 Therefore, despite
some studies showing a beneficial effect of rifampicin, the
expert group does currently not recommend rifampicin for
streptococcal FRI infections.27,45
Treatment of Enterococcus Species
If enterococci (especially Enterococcus faecalis) are
sensitive to ampicillin or amoxicillin, this should be the initial
agent of choice, with up to a week intravenous therapy fol-
lowed by oral amoxicillin.
For ampicillin-resistant enterococci, vancomycin and
daptomycin are the first choices. Resistance to vancomycin is
increasing (vancomycin-resistant enterococci). Apart from
daptomycin or oral linezolid, often no other alternative
options are available. Pristinamycin may be considered for
treatment of E. faecalis, although evidence supporting this is
limited for enterococcal implant-related infections.29,30,33,49
IV fosfomycin has extensive tissue penetration in
inflamed tissue and bone. In an experimental model of
foreign-body infection, the combination of fosfomycin and
gentamicin showed good biofilm activity against E. faeca-
lis.50 Further studies are needed before IV fosfomycin can
be recommended as a standard therapy in enterococcal FRI,
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although it may be considered in selected cases.51 No safety
data exist on long-term oral administration of fosfomycin.
This route of administration is therefore not recommended
for bone and joint infections.
Treatment of Enterobacteriaceae
If Enterobacteriaceae are cultured, an anti–Gram-
negative agent should be administered (ideally a narrower
beta-lactam agent if possible) in line with the antibiogram.
Once susceptibilities are available and the wound is dry, an
oral fluoroquinolone may be appropriate as monotherapy. Flu-
oroquinolones are able to eliminate Gram-negative rods in
young biofilms and have excellent bioavailability. Unfortu-
nately, selection of resistance to fluoroquinolones is common
when there is a high bioburden, so they should only be started
after surgical debridement.12,13 Furthermore, the risk of super-
infection with selected fluoroquinolone-resistant strains from
the skin microbiome is highest during the early postoperative
period, when the patient has drains and an oozing wound.
When there is fluoroquinolone resistance, oral
sulfamethoxazole/trimethoprim in high dose (800/160 mg, 8
hourly) or continuation of beta-lactam agents is recommen-
ded. Sulfamethoxazole/trimethoprim has poor biofilm activity
by which it is regarded as a suppressive rather than curative
therapy.52
IV fosfomycin showed biofilm activity against Escher-
ichia coli in vitro and in an experimental model of foreign-
body infection, and may be considered as an additional anti-
biotic against Gram-negative FRI in selected cases, caused by
susceptible bacteria.53
For some carbapenemase-producing Enterobacteria-
ceae, other agents such as tigecycline, intravenous fosfomy-
cin, or colistin, in combination treatment, may need to be
considered. Expert microbiology advice should be sought for
any of these infections.
Treatment of Nonfermenters
For nonfermenters such as Pseudomonas aeruginosa,
fluoroquinolones are not recommended as initial treatment
after debridement because of the high rate of resistance that
can develop. Although the bactericidal action of beta-lactams
appears inferior to fluoroquinolones,54 beta-lactam antibiotics
such as piperacillin/tazobactam, cefepime, ceftazidime, or
a carbapenem (except ertapenem) should be used as the initial
therapy. There is some in vitro evidence of a decrease in the
rate of bacterial killing with a high inoculum, and so, the
addition of an aminoglycoside for 2–5 days can be
considered.55
If P. aeruginosa is resistant to fluoroquinolones,
there are no other suitable oral agents and beta-lactams
need to be continued intravenously according to suscepti-
bility testing.
Pseudomonas spp. and other nonfermenters such as
Acinetobacter spp. may be multiresistant but sensitive to
colistin. Colistin should be used in combination therapy with
careful monitoring of renal function and trough serum dos-
ages, as it is associated with a high risk of nephrotoxicity.
Tigecycline may be an alternative for some organisms, but
not for P. aeruginosa because of intrinsic resistance to the
agent. Expert microbiology advice should be sought for any
of these infections.
Treatment of Anaerobes
In the group of Gram-positive anaerobes, Cutibacte-
rium (previously Propionibacterium) acnes is most frequently
isolated).56 Cutibacterium acnes is highly susceptible to
a wide range of antibiotics except metronidazole; however,
resistance is emerging against macrolides, clindamycin, doxy-
cycline, or minocycline and trimethoprim-sulfamethoxa-
zole.57–60 In biofilm-related infections, vancomycin,
levofloxacin, and clindamycin are less effective, while rifam-
picin, daptomycin, and ceftriaxone have demonstrated biofilm
activity in animal models. In combination, rifampicin and
levofloxacin show good efficacy.57,61 We recommend starting
with benzylpenicillin or ceftriaxone, followed by oral treat-
ment of rifampicin in combination with amoxicillin, doxycy-
cline, or quinolones. For other Gram-positive anaerobes (eg,
Finegoldia magna, Peptostreptococcus species, and Clostrid-
ium species), there are no studies to guide treatment. Penicil-
lin (or ceftriaxone) would be a good initial therapy, and
treatment should be guided by speciation, susceptibilities,
and microbiological advice.
Gram-negative anaerobes should be treated with IV
ampicillin/sulbactam or amoxicillin/clavulanic acid based on
availability, followed by oral metronidazole.
Treatment of Candida Species
Little is published regarding the treatment of FRI
caused by Candida or any other fungal species. There are
no published guidelines even for PJI. Azzam et al62 suggested
that debridement with implant retention is not sufficient to
control the infection. Although a few studies have shown
a successful outcome with debridement and antifungal ther-
apy,63–65 the IDSA guidelines recommend removal of the
implant in PJI. In cases of FRI, we also recommend removal
TABLE 2. Key Recommendations on Antimicrobial Therapy
For the antimicrobial treatment of FRI, the presence of a biofilm, fracture
stability, and fracture consolidation are important determinants that should
be key determinants in the decision-making process.
If there are confirmatory or suggestive signs of FRI, empiric intravenous
antimicrobial therapy should be started immediately after peroperative
tissue sampling.
Empiric therapy should be broad spectrum including a lipo/glycopeptide and
an agent covering Gram-negative bacilli. Thereafter, it should be narrowed
according to culture results as soon as possible.
IV antibiotics can be switched to appropriate bioavailable oral agents—if
applicable—as soon as definite culture, and sensitivity results are known.
The earlier recommendation of fixed initial 2 wk of IV antibiotic therapy
can be abandoned.
Targeted antibiotic therapy should be guided by the retrieved pathogens and
the surgical strategy.
Expert microbiology/ID physician advice should always be sought especially
when there is antimicrobial resistance, intolerance, or risk of drug
interactions.
Antibiotics should be used prudently and in line with the principles of good
antimicrobial stewardship.
ID physician, infectious diseases physician.
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of all foreign material. Various authors have studied the use
of antifungals in Candida biofilms. Echinocandins have the
ability to treat Candida biofilms and may have a better fun-
gicidal and anti-biofilm action than azoles.66,67 Amphotericin
B has as good activity, but is more toxic than echinocandins
and can cause renal dysfunction.67–69 When the Candida spp.
is sensitive to fluconazole, this is a useful oral follow-on
treatment.62,67 It is recommended to continue treatment until
bone consolidation is achieved and removal of the implant is
possible without compromising stability.
Treatment of Polymicrobial Infections
A high percentage of patients with FRI are diagnosed
with a polymicrobial infection. Studies indicate that this can
be up to one-third of the FRI population.70,71 Furthermore,
within the group of polymicrobial infections, there seems to
be a high resistance rate of up to 30%. Therefore, broad-
spectrum empiric therapy in FRI should be strongly consid-
ered.70 Treatment should be tailored to the individual patient
and culture results, as described in the sections above. Expert
microbiology advice should be sought for any of these
infections.
Treatment of Culture-Negative Infections
The exact rate of culture-negative infections in fracture
care is unknown. Previous studies published rates that varied
between 1% and 16%.72–74 However, the rate of undetected,
culture-negative FRIs may be higher, especially in nonun-
ions.75,76 Reasons that cultures remain negative are previous
antibiotic treatment before tissue sampling, too few samples
(ie, ,3 tissue samples) taken during surgery, incorrect local-
ization of sampling, or infections with difficult-to-grow/-to
detect organisms. Adequate treatment of culture-negative
FRI is severely hampered since antibiotics cannot be targeted
to a specific pathogen. Therefore, additional methods to
increase pathogen detection, such as implant sonication or
molecular techniques (ie, polymerase chain reaction), should
be considered in such cases.75,77
If a confirmed FRI stays culture-negative, antibiotic
treatment should be chosen to cover the most likely pathogens
(Table 1). If cultures are negative but the diagnosis of the FRI
is not confirmed, the preferred option is to withhold empirical
antibiotic treatment to observe the clinical evolution, and to
eventually repeat tissue sampling if possible, this allows the
avoidance of antibiotic toxicity and the risk of selecting anti-
biotic resistance.
Outpatient Parenteral Antibiotic Therapy
The use of outpatient parenteral antibiotic therapy
(OPAT) has increased in recent years. It has several
advantages, such as shortening the hospital stay, diminishing
the risk of nosocomial infections, and lower costs.78 The most
useful agents for OPAT are those that can be administered
once daily. Intravenous agents that can be given once daily
include ceftriaxone, teicoplanin, daptomycin, and ertapenem.
Vancomycin can be used in OPAT, but should be adminis-
tered twice daily with a lengthy infusion each time. Fluclox-
acillin infusions, using elastomeric pumps, have been used
successfully in the community for MSSA infections.
Elastomeric pumps can also be used for other antimicrobial
agents such as, vancomycin, piperacillin/tazobactam, and
cefepime.79
Not every hospital has the resources to organize OPAT
therapy. Therefore, the expert group has no specific recom-
mendations for its use in FRI. Where possible an early switch
to highly bioavailable, well-tolerated oral antibiotics is the
preferred option.
CONCLUSION
Research focusing on systemic antibiotic therapy in FRI
is scarce, and attention primarily focuses on PJI. To improve
the overall outcome of patients with FRI, there is an urgent
need for standardized recommendations for antimicrobial
therapy. This review focuses on delivering these recommen-
dations (Table 2), in combination with optimal treatment
pathways for FRI patients (Fig. 1) based on up-to-date scien-
tific evidence and expert opinion.
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